[1]刘 芳,季 良,姜海燕,等.肝爽颗粒联合富马酸替诺福韦二吡呋酯片对乙型病毒性肝炎肝硬化患者APRI、FIB-4的影响[J].医学信息,2021,34(05):104-106.[doi:10.3969/j.issn.1006-1959.2021.05.029]
　LIU Fang,JI Liang,JIANG Hai-yan,et al.The Effect of Ganshuang Granule Combined with Tenofovir Disoproxil Fumarate Tablets on APRI and FIB-4 in Patients with Hepatitis B Liver Cirrhosis[J].Medical Information,2021,34(05):104-106.[doi:10.3969/j.issn.1006-1959.2021.05.029]
点击复制

肝爽颗粒联合富马酸替诺福韦二吡呋酯片对乙型病毒性肝炎肝硬化患者APRI、FIB-4的影响()
分享到：

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
34卷
期数:
2021年05期
页码:
104-106
栏目:
论著
出版日期:
2021-03-01

文章信息/Info

Title:
The Effect of Ganshuang Granule Combined with Tenofovir Disoproxil Fumarate Tablets on APRI and FIB-4 in Patients with Hepatitis B Liver Cirrhosis
文章编号:
1006-1959（2021）05-0104-04
作者:
刘 芳; 季 良; 姜海燕; 等
（1.佳木斯市中心医院感染科，黑龙江 佳木斯 154002 2.佳木斯大学公共卫生学院，黑龙江 佳木斯 154002）
Author(s):
LIU Fang; JI Liang; JIANG Hai-yan; et al.
(1.Department of Infectious Diseases,Jiamusi Central Hospital,Jiamusi 154002,Heilongjiang,China; 2.School of Public Health,Jiamusi University,Jiamusi 154002,Heilongjiang,China)
关键词:
富马酸替诺福韦二吡呋酯片; 肝硬化; 肝爽颗粒; 乙型病毒性肝炎; APRI; FIB-4
Keywords:
Tenofovir disoproxil fumarate tablets; Liver cirrhosis; Ganshuang granules; Viral hepatitis B; APRI; FIB-4
分类号:
R575.2
DOI:
10.3969/j.issn.1006-1959.2021.05.029
文献标志码:
A
摘要:
目的 研究肝爽颗粒联合富马酸替诺福韦二吡呋酯片对乙型病毒性肝炎肝硬化患者APRI、FIB-4的影响。方法 选择2017年8月~2020年8月我院100例乙肝肝硬化患者为研究对象，随机分为观察组和对照组，各50例。对照组口服富马酸替诺福韦二吡呋酯片治疗，观察组在对照组基础上联用肝爽颗粒治疗。比较两组疗效，ALB、ALT、TBIL、PLT、AST水平，APRI、FIB-4水平及PCⅢ、HA、LN、Ⅳ-C水平。结果 观察组有效率为92.00%，高于对照组的70.00%，差异有统计学意义（P＜0.05）；两组ALB、ALT、TBIL、PLT和AST水平均降低，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组APRI和FIB-4均降低，且观察组低于对照组，差异有统计学意义（P＜0.05）；两组血清PCⅢ、HA、LN和Ⅳ-C水平均降低，且观察组低于对照组，差异有统计学意义（P＜0.05）。结论 富马酸替诺福韦二吡呋酯片联合肝爽颗粒可以降低乙肝肝硬化患者的APRI和FIB-4，改善肝功能，减轻肝纤维化程度。
Abstract:
Objective To study the effect of Ganshuang granule combined with tenofovir disoproxil fumarate tablets on APRI and FIB-4 in patients with hepatitis B cirrhosis.Methods From August 2017 to August 2020, 100 patients with hepatitis B cirrhosis in our hospital were selected as the research objects, and they were randomly divided into observation group and control group, with 50 cases in each group.The control group was treated with tenofovir disoproxil fumarate tablets orally, and the observation group was treated with Ganshuang granules on the basis of the control group.The curative effects of the two groups were compared, the levels of ALB, ALT, TBIL, PLT, AST, the levels of APRI, FIB-4, and the levels of PCⅢ, HA, LN, and IV-C.Results The effective rate of the observation group was 92.00%, which was higher than 70.00% of the control group,the difference was statistically significant (P＜0.05);The levels of ALB, ALT, TBIL, PLT and AST in the two groups were reduced, and the observation group was lower than the control group, the difference was statistically significant (P＜0.05);Both APRI and FIB-4 decreased in the two groups, and the observation group was lower than the control group, the difference was statistically significant (P＜0.05);The levels of serum PCⅢ, HA, LN and Ⅳ-C in the two groups decreased, and the observation group was lower than the control group, the difference was statistically significant (P＜0.05).Conclusion Tenofovir disoproxil fumarate tablets combined with Ganshuang granules can reduce APRI and FIB-4 in patients with hepatitis B cirrhosis, improve liver function, and reduce liver fibrosis.

参考文献/References:

[1]赵海燕,杨东,洪伟,等.慢性乙型肝炎、乙肝肝硬化患者中HBV-DNA水平、HBV-M、淋巴细胞亚型特点分析[J].广东医学,2019,40(3):432-435. [2]姚仲彩,蔡亚军,石勇明,等.大黄蛰虫胶囊联合恩替卡韦对乙肝肝硬化患者肝纤维化及T细胞亚群的影响[J].广东医学,2019,40(22):3141-3146. [3]刘祖明,邹灿.乙肝肝硬化患者FibroScan参数与血清炎症指标、胶原代谢指标及纤维化指标的相关性[J].海南医学院学报,2018,24(5):597-600. [4]陈娟娟,张瑞,陈保站,等.恩替卡韦治疗对乙肝肝硬化患者肝功能及肝硬化指标的影响[J].中国医院药学杂志,2018,38(14):1526-1529. [5]中华医学会肝病学分会中华医学会感染病学分会.慢性乙型肝炎防治指南2010年更新版[J].中华实验和临床感染病杂志(电子版),2011,12(1):50-60. [6]黄红刚.大黄蟅虫丸联合抗病毒治疗对慢性乙肝肝硬化患者血清病毒复制指标及免疫,炎症指标的影响[J].海南医学院学报,2017,23(8):1048-1051. [7]赫伟丽,苑晓晨,赵帆,等.益气解毒通络颗粒对乙肝肝硬化患者肝星状细胞标记物VEGF和PDGF-AB的影响[J].世界中医药,2018,13(11):73-78. [8]赵彩红,田志颖,张丽贤,等.乙肝肝硬化患者中微小RNA-21、Th9的表达及其对肠道屏障功能调控机制的影响[J].实用医学杂志,2019,35(8):20-23. [9]谢函君,叶志伟.乙肝肝硬化患者病毒血清标志物及外周血小板计数与肝纤维化程度的相关性[J].实用临床医药杂志,2019,23(4):63-65,69. [10]高志荣,李青松,滕晓生.复方甘草酸苷片联合恩替卡韦治疗乙肝肝硬化患者的疗效观察[J].中国药物与临床,2019,19(9):1490-1492. [11]陈莹,李继昌,刘海霞,等.醋酸奥曲肽联合前列地尔对乙肝肝硬化合并肝肾综合征患者血清炎性因子的影响[J].实用临床医药杂志,2018,22(21):58-60. [12]田长印.肝爽颗粒联合多烯磷脂酰胆碱治疗慢性乙型肝炎的临床研究[J].现代药物与临床,2019,34(9):2761-2764. [13]孙海青,王小琪,时红波,等.肝爽颗粒对CCl4诱导的慢性肝损伤小鼠模型和肝损伤细胞模型的保护作用[J].临床肝胆病杂志,2015,31(7):1114-1119. [14]丁德平,刘平,陈琳莉,等.FibroScan,AAR,APRI,FIB-4及其联合应用对乙型肝炎患者肝纤维化程度诊断效价的意义[J].中西医结合肝病杂志,2016,26(5):267-269,286. [15]张耀武.恩替卡韦分散片联合肝爽颗粒治疗失代偿期乙型肝炎肝硬化患者临床观察[J].实用肝脏病杂志,2013,16(6):550-551.

相似文献/References:

[1]崔 洁.凝血酶原时间与血小板检验方式对诊断肝硬化疾病的临床价值研究[J].医学信息,2018,31(04):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
　CUI Jie.Study on the Clinical Value of Prothrombin Time and Platelet Examination in the Diagnosis of Liver Cirrhosis[J].Medical Information,2018,31(05):150.[doi:10.3969/j.issn.1006-1959.2018.04.055]
[2]祁兴顺,周新苗,许向波,等.肝硬化患者应用特利加压素治疗期间发生 低钠血症的现状研究[J].医学信息,2018,31(09):1.[doi:10.3969/j.issn.1006-1959.2018.09.001]
[3]桂志兵,汪文生.红细胞分布宽度与血小板计数比值在乙型肝炎肝硬化患者病情评估中的作用[J].医学信息,2018,31(20):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
　GUI Zhi-bing,WANG Wen-sheng.The Role of Red Blood Cell Distribution Width and Platelet Ratio in the Evaluation of Patients with Hepatitis B Cirrhosis[J].Medical Information,2018,31(05):65.[doi:10.3969/j.issn.1006-1959.2018.20.019]
[4]王晓刚.利拉鲁肽联合胰岛素泵对2 型糖尿病合并肝硬化患者血糖代谢及肝纤维化的影响[J].医学信息,2018,31(20):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
　WANG Xiao-gang.Effects of Liraglutide Combined with Insulin Pump on Blood Glucose Metabolism and Liver Fibrosis in Patients with Type 2 Diabetes Mellitus Complicated with Cirrhosis[J].Medical Information,2018,31(05):136.[doi:10.3969/j.issn.1006-1959.2018.20.041]
[5]赵华莹,李运泽,韦天灵,等.肝硬化合并门静脉血栓形成的危险因素分析[J].医学信息,2019,32(03):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
　ZHAO Hua-ying,LI Yun-ze,WEI Tian-ling,et al.Analysis of Risk Factors for Cirrhotic Patients with Portal Vein Thrombosis[J].Medical Information,2019,32(05):86.[doi:10.3969/j.issn.1006-1959.2019.03.026]
[6]张宏程.生长抑素联合泮托拉唑治疗肝硬化合并上消化道出血的疗效观察[J].医学信息,2019,32(03):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
　ZHANG Hong-cheng.Therapeutic Effect of Somatostatin Combined with Pantoprazole on Hepatic Cirrhosis Complicated with Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(05):153.[doi:10.3969/j.issn.1006-1959.2019.03.050]
[7]张许林,余泽波.肝硬化上消化道出血的输血治疗进展[J].医学信息,2019,32(08):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
　ZHANG Xu-lin,YU Ze-bo.Progress in Transfusion Therapy for Upper Gastrointestinal Hemorrhage[J].Medical Information,2019,32(05):85.[doi:10.3969/j.issn.1006-1959.2019.08.025]
[8]陈 杰.左旋肉碱治疗肝硬化并显性肝性脑病的效果观察[J].医学信息,2019,32(14):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
　CHEN Jie.Effect of L-carnitine on Liver Cirrhosis and Dominant Hepatic Encephalopathy[J].Medical Information,2019,32(05):153.[doi:10.3969/j.issn.1006-1959.2019.14.051]
[9]曹 宇,何其顺,郭雅雯,等.延时扫描对肝硬化患者肝脏增强CT检查中动脉期时相的影响[J].医学信息,2020,33(01):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]
　CAO Yu,HE Qi-shun,GUO Ya-wen,et al.Effect of Delayed Scanning on the Phase of the Middle Arterial Phase of Liver Enhanced CT in Patients with Cirrhosis[J].Medical Information,2020,33(05):161.[doi:10.3969/j.issn.1006-1959.2020.01.053]
[10]张小雨,严 艳.自身免疫性肝炎合并自身免疫性疾病的特征研究[J].医学信息,2020,33(02):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]
　ZHANG Xiao-yu,YAN Yan.Study on the Characteristics of Autoimmune Hepatitis Combined with Autoimmune Diseases[J].Medical Information,2020,33(05):89.[doi:10.3969/j.issn.1006-1959.2020.02.024]

更新日期/Last Update: 1900-01-01